
CODEXIS INC
CDXSNASDAQTrading Snapshot
- Day Range
- $1.62 β $1.66
- 52-Week Range
- $0.96 β $3.87
- Volume
- $4.48B
- Avg Volume
- $5.15B
- Shares Outstanding
- 107.6M
- Next Earnings
- Aug 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $70M
- Last Q Revenue
- $15M
- P/E Ratio
- β
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-0.36
- Dividend Yield
- β
Why Investors Own CDXS
- βHigh-growth profile β revenue up +51.7% YoY with expanding US Equity exposure.
- βHealthy economics β 68% gross margin and 12% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CODEXIS INC
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
CODEXIS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift CDXS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
CODEXIS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.